Optimum platelet inhibition after coronary artery bypass surgery: a prospective, randomised trial comparing platelet aggregation using low- and medium-dose aspirin and clopidogrel

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2003
INTERVENTION: Patients will be randomised into treatment allocation to receive either 100 mg aspirin, 325 mg aspirin or identically encapsulated 75 mg clopidogrel daily for 5 days. CONDITION: Coronary artery bypass grafting (CABG) ; Surgery PRIMARY OUTCOME: Platelet aggregation ratio at 5 days. SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: 72 Patients and 36 controls will be recruited from patients proceeding to coronary artery bypass surgery.
Epistemonikos ID: cf65289fcea5b77ccb56a4e6f738ca26034d8189
First added on: Aug 21, 2024